Buscar
Disc Medicine Inc
IRONAñadir a la lista de seguimiento
77.000USD
-2.210-2.79%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.96BCap. mercado
PérdidaP/E TTM
Más Datos de Disc Medicine Inc Compañía
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Información de Disc Medicine Inc
Símbolo de cotizaciónIRON
Nombre de la empresaDisc Medicine Inc
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoQuisel (John D)
Número de empleados84
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 12
Dirección321 Arsenal Street, Suite 101
CiudadWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Teléfono16176749274
Sitio Webhttps://www.discmedicine.com/
Símbolo de cotizaciónIRON
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoQuisel (John D)
Ejecutivos de Disc Medicine Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Disc Medicine Inc?
Los cinco principales accionistas de Disc Medicine Inc son: Dr. Rahul Khara, Pharm.D.
¿Cuántas instituciones poseen acciones de Disc Medicine Inc (IRON)?
A fecha de 2026Q1, 399 instituciones poseen acciones de Disc Medicine Inc, con un valor de mercado combinado de aproximadamente 42.26M, lo que representa el 110.63% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1071670.00.